WYETH’S first-quarter earnings rose 44% as sales of its vaccine against childhood infections more than doubled and sales of arthritis treatment Enbrel and other prescription drugs rose.

WYETH said second-quarter profit fell 4.3%, a smaller decline than analysts expected.